Emergent BioSolutions (EBS) Receivables (2010 - 2026)
Emergent BioSolutions (EBS) reported Receivables of $94.1 million for Q3 2026, down 44.3% from $168.8 million a year earlier and down 55.4% from the prior quarter.
Powered by 
Analysis
Emergent BioSolutions (EBS) Receivables (2010 - 2026) Analysis & Trends
At the end of FY2025, Emergent BioSolutions posted Receivables of $102.4 million, down 41.2% from FY2024.
- Receivables has a five-year compound annual growth rate of -18.7% (FY2020 to FY2025).
- By year, Receivables came in at $174.1 million in FY2024 (-28.2%), $242.4 million in FY2023 (+12.0%), $216.4 million in FY2022 (-34.5%) and $330.5 million in FY2021 (+14.3%).
- The Q3 2026 figure ranks as the lowest quarterly Receivables since Q3 2018.
- Year over year, Receivables gained in two of the last eight quarters, with an average decline of 13.3%.
- The high point for year-over-year Receivables in five years was Q2 2026 (growth of 105.6%); the low point was Q2 2025 (a decline of 63.2%).
- Per Business Quant data, the three quarters before Q3 2026 came in at $211.2 million (Q2 2026), $139.9 million (Q1 2026) and $102.4 million (Q4 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,264.65 Bn | 1,238.27 Bn | 20.46 Bn | 25.23 Bn |
| 2 | Johnson & Johnson | 677.74 Bn | 597.60 Bn | 17.30 Bn | 18.99 Bn |
| 3 | AbbVie | 517.10 Bn | 485.11 Bn | 13.12 Bn | 13.51 Bn |
| 4 | Merck | 362.23 Bn | 325.17 Bn | 13.19 Bn | 12.74 Bn |
| 5 | Novartis Ag | 315.90 Bn | 276.16 Bn | 11.24 Bn | 9.64 Bn |
| 6 | Astrazeneca | 289.40 Bn | 266.24 Bn | 12.86 Bn | 14.33 Bn |
| 7 | Amgen | 249.90 Bn | 201.56 Bn | 7.58 Bn | 10.35 Bn |
| 8 | Gilead Sciences | 209.15 Bn | 184.26 Bn | 6.73 Bn | 5.01 Bn |
| 9 | Pfizer | 165.88 Bn | 113.23 Bn | 12.56 Bn | 14.19 Bn |
| 10 | Emergent BioSolutions | 310.37 Mn | -370.73 Mn | 29.20 Mn | 94.10 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 94.10 Mn |
| Jun 30, 2026 | 211.20 Mn |
| Mar 31, 2026 | 139.90 Mn |
| Dec 31, 2025 | 102.40 Mn |
| Sep 30, 2025 | 168.80 Mn |
| Jun 30, 2025 | 102.70 Mn |
| Mar 31, 2025 | 234.60 Mn |
| Dec 31, 2024 | 174.10 Mn |
| Sep 30, 2024 | 140.50 Mn |
| Jun 30, 2024 | 278.80 Mn |
| Mar 31, 2024 | 275.10 Mn |
| Dec 31, 2023 | 242.40 Mn |
| Sep 30, 2023 | 277.50 Mn |
| Jun 30, 2023 | 341.90 Mn |
| Mar 31, 2023 | 205.70 Mn |
| Dec 31, 2022 | 216.40 Mn |
| Sep 30, 2022 | 261.50 Mn |
| Jun 30, 2022 | 230.10 Mn |
| Mar 31, 2022 | 248.40 Mn |
| Dec 31, 2021 | 330.50 Mn |
API Access
Emergent BioSolutions Receivables API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=receivables&ticker=EBS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "receivables", "ticker": "EBS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=receivables&ticker=EBS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();